Published in Cancer Weekly, September 8th, 1997
CD80 (B7-1) and CD86 (B7-2) are co-stimulatory molecules, which when transfected onto tumor cells, represent a means of augmenting the immunogenicity of the tumor cells to induce a host immune response directed against the tumor antigens.
In previous research, German researchers Wolfgang Rudy and colleagues demonstrated that this immune response was not always sufficient enough to induce T-cell proliferation (A. Habicht and W. Rudy et al., Eur. J. Cancer, 1995;31A:2396).
In their current...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.